{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-212487","form_type":"8-K","ticker":"CRIS","cik":"0001108205","company_name":"CURIS INC","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.000620+00:00","generated_at":"2026-06-24T03:41:52.844029+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Curis Q2 net loss widens to $15.9M; appoints new CFO; emavusertib combo shows tumor reduction in 8 of 9","bullets":["Net loss of $15.9M ($0.17/sh) vs $10.8M ($0.12) in Q2 2021; revenue flat at $2.4M.","Cash and investments $107.2M as of June 30, 2022; cash runway expected into 2024.","Emavusertib + ibrutinib combo: tumor reduction in 8 of 9 evaluable patients; 2 CR, 2 PR; potential to overcome ibrutinib resistance.","Appointed Diantha Duvall as CFO effective Aug 5, 2022, succeeding Bill Steinkrauss (resigning).","Working with FDA to resolve partial clinical holds on emavusertib enrollment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-212487","json":"https://secwatch.observer/filing/0001193125-22-212487.json","markdown":"https://secwatch.observer/filing/0001193125-22-212487.md","text":"https://secwatch.observer/filing/0001193125-22-212487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108205/000119312522212487/0001193125-22-212487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1108205/000119312522212487/d249846d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:41:52.844029+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fc6742cb37","claim":"Diantha Duvall was appointed as Chief Financial Officer at CURIS INC.","evidence_excerpt":"On August 4, 2022, the Board of Directors (the “Board”) of the Company appointed Diantha Duvall to the position of chief financial officer, treasurer, assistant secretary, principal financial officer and principal accounting officer of the Company effective as of August 5, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1108205/000119312522212487/0001193125-22-212487-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}